Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study
Long-term SZC use is associated with significant reductions in hyperkalemia-related hospitalizations or emergency department visits compared with short-term use among patients with heart failure or cardio/renal dysfunction.
Authors
- Abiy Agiro (ORCID: https://orcid.org/0000-0002-2369-8507)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Manasvi Sundar (ORCID: https://orcid.org/0000-0001-5858-8685)
- Fan Mu (ORCID: https://orcid.org/0000-0003-0252-0387)
- Arun Malhotra (ORCID: https://orcid.org/0000-0001-6656-7841)
- Jingyi Chen (ORCID: https://orcid.org/0009-0007-0141-2241)
- Ellen Colman
- Ali Greatsinger
- Angela Zhao (ORCID: https://orcid.org/0009-0000-5508-2603)
Institutions
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1007/s40801-025-00525-7
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca